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Idiopathic membranous nephropathy: Definition and relevance
of a partial remission.
Background. Membranous nephropathy (MGN) remains the
most common cause of adult onset nephrotic syndrome, and
within the primary glomerulonephritis group is a leading cause
of renal failure. A complete remission (CR) confers an excel-
lent long-term prognosis, but the quantitative benefits of partial
remissions (PR) have not been defined.
Methods. This study evaluated the rate of renal function de-
cline (slope), relapse, and renal survival in nephrotic MGN pa-
tients with CR, PR, or no remission (NR). Multivariate analysis
included clinical and laboratory data at presentation and over
follow-up, blood pressure control and agents employed, and
immunosuppressive therapy.
Results. The study cohort consisted of 348 nephrotic MGN
patients with a minimum of 12 months follow-up identified
from the Toronto Glomerulonephritis Registry. Over a median
follow-up of 60 months, 102 experienced a CR, 136 had a PR,
and 110 had no remission. A PR was independently predictive
of slope and survival from renal failure by multivariate analysis
(hazard ratio 0.08, 95%CI 0.03–0.19, P < 0.001). Benefit from
immunosuppression could only be shown in a subset of high-risk
patients. Treatment-related PR had the same long-term impli-
cation as spontaneous ones. Relapses from PR were high (47%)
but often reversible.
Conclusion. A partial remission is an important therapeu-
tic target with implications for both progression rate and renal
survival.
Idiopathic membranous nephropathy (MGN) remains
the most common cause of primary nephrotic syndrome
in adults. The natural history of untreated MGN has been
widely reported, with most series finding a complete re-
mission rate of 20% to 30% and a 60% to 80% 10-year
renal survival [1–5].
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Severity of proteinuria at onset and during follow-up
has been associated with outcome in most studies [5–9].
Although there is evidence that nephrotic patients who
experience a CR have a favorable long-term prognosis
[10, 11], the long-term outcome of those with only a re-
duction in proteinuria has not been reported. Despite
the lack of specific evidence of the value of a reduction in
proteinuria in MGN as a valid surrogate for renal failure,
this outcome is frequently reported as a positive finding
in randomized controlled trials [12–15].
This study addresses the long-term outcome of a partial
remission (PR) in nephrotic MGN patients. It compares
the rate of renal function decline, relapse, renal failure,
and treatment among patients with a PR, CR, and no
remission (NR).
METHODS
All MGN patients from the Toronto glomerulonephri-
tis registry were considered for this study. This database
began in 1974 and includes all biopsy-proven cases of
glomerulonephritis from the Toronto area. Patient infor-
mation at onset is compiled using a standard form, and
registrars perform a periodic prospective assessment of
the patient’s clinical status, medication, and laboratory
results [16]. This study focuses on nephrotic MGN pa-
tients older than 16 years at presentation with at least
12 months follow-up.
Parameters collected
Demographics were age and body mass index (BMI) at
onset, sex, and race. Parameters collected included both
initial and follow-up information on systolic and diastolic
blood pressure, weight, serum creatinine, and 24-hour
urine protein and creatinine. Also recorded was exposure
to immunosuppressive agents and antihypertensive med-
ications, including the angiotensin-converting enzyme in-
hibitor (ACEi) and angiotensin receptor blocker (ARB)
classes of drugs.
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Definitions
Creatinine clearance (CrCl) values were adjusted for
age, sex, and weight using the Cockcroft-Gault method
[17]. Nephrotic patients were identified by a proteinuria
value ≥3.5 g/day at any point during follow-up. A CR was
defined by a proteinuria value ≤0.3 g/day. A PR was de-
fined by a proteinuria value <3.5 g/day plus a 50% reduc-
tion from its peak value [15]. A relapse was a proteinuria
value ≥3.5 g/day after any remission. Subjects that had
both a PR and a CR were only included in the CR group.
Time to remission was calculated from the first clinical
assessment suggestive of renal disease (abnormal pro-
teinuria or serum creatinine). Renal failure was defined
as a CrCl ≤15 mL/min at last follow-up, the start of dialy-
sis, or a renal transplantation. Remissions in proteinuria
were not ascribed if the CrCl was ≤15 mL/min at that pro-
teinuria time point. Mean arterial pressure (MAP) was
defined as the diastolic plus a third of the pulse pressure.
For each patient, an average MAP was determined for
each six-month period of follow-up. Time-average MAP
represents the average of every period’s mean.
Immunosuppressive treatment is reported as intent to
treat regardless of the duration of therapy. Patients are
categorized as having received no, mono-, or dual im-
munosuppressive therapy [11]. This last group was de-
fined by a minimum of 10 mg of prednisone plus at least
1.5 mg/kg of azathioprine or cyclosporine, or 1 mg/kg
of cyclophosphamide or 0.15 mg/kg of chlorambucil or
1000 mg of mycophenolate mofetil. Monotherapy was
defined as exposure to any form of immunosuppressive
treatment that did not satisfy the dual therapy definition
(e.g., steroids alone). Therapy with ACEi or ARB is pre-
sented as any exposure.
Statistical analysis
Continuous variables were tested for normality using
Q-Q and box-plot analysis. Normally distributed vari-
ables were expressed as mean ± standard deviation and
compared using Student t test, one-way analysis of vari-
ance (ANOVA) (with post-hoc analysis using the least
significant difference method for significant results), or
Pearson test. Nonparametric variables were expressed
as median and range and compared using either Mann-
Whitney or Kruskal-Wallis test. Categorical variables
were expressed in percentage and compared using chi-
square test.
The rate of renal function decline (slope) and renal fail-
ure were the two definitive outcomes used to validate PR
as an appropriate surrogate for outcome in MGN. The
slope was determined by fitting a straight line through
the calculated CrCl using the principle of least squares.
This was plotted and visually examined in each patient.
Slopes were also calculated to remission point and from
remission onward in those with a minimum of 12 months’
follow-up before and after remission and compared using
a paired t test. Periods of reversible acute renal failure de-
fined as a rapid reduction and recovery in CrCl of ≥40%
within a month were censored.
Univariate analysis followed by multiple linear regres-
sion was used to determine independent explanatory
variables of slope. Only variables associated by univari-
ate analysis were included by forward stepwise entry in a
multivariate model.
Survival analysis was performed to test the associa-
tion between renal failure and each parameter collected.
Survival times for each patient were obtained from first
clinical assessment to last follow-up. Univariate compar-
isons of renal survival were done by Kaplan-Meier curves
and log-rank test. A Cox proportional hazard model was
constructed to determine independent variables associ-
ated with this outcome. Similar to slope analysis, only
variables associated by univariate analysis were included
in the multivariate model. Different methods of variable
entry (backward or block entry) and testing models with
clinically relevant variables not associated by univariate
analysis were also examined to see if the interaction be-
tween our variable of interest (PR) and outcome (slope
and renal failure) was consistent [18].
Patients with PR were compared to those with CR and
NR to identify variables predicting the type of remission.
This analysis used only information up until remission for
PR and CR. In addition, patients with a spontaneous PR
were compared to those with a PR in the setting of im-
munosuppressive therapy. Finally, the impact of relapse
from PR was evaluated.
All P values were two-tailed, and values less than 0.05
were considered statistically significant. Confidence in-
tervals (CI) included 95% of predicted values. Analyses
were carried out using SPSS software (version 11, SPSS,
Inc., Chicago, IL, USA).
RESULTS
There were 520 patients with a diagnosis of MGN with
clinical information available in the Toronto glomeru-
lonephritis registry from 1974 to the end of March 2003.
Lupus membranous nephropathy is a separate category
and was not included within this group. Exclusions were
94 patients with less than 12 months’ follow-up, 20 with
secondary membranous nephropathy, 8 less than 16 years
of age at presentation, three who developed a rapid de-
terioration in renal function secondary to an additional
renal disease, and six that had neither proteinuria nor
weight measured. In the remaining 389 subjects, 41 were
never nephrotic, and 348 were nephrotic at some time
during their follow-up. The latter cohort is the subject of
this report.
The cohort’s baseline characteristics, follow-up, and
outcomes are summarized in Table 1. Overall, 136
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Table 1. Baseline characteristic and outcome in 348 nephrotic MGN
patients
N 348
At onset
Age years 48 ± 15
Sex (% female) 31
Ethnicity %
Caucasian 79
African American 5
Asian 4
Other 12
MAP mm Hg 103 ± 13
CrCl mL/min 84 ± 33
Proteinuria g/d 6.3 (0.5–31.3)
Follow-up
Duration of follow-up months 60 (12–400)
MAP mm Hg 101 ± 9
Immunosuppression %
None 39
Mono 45
Dual 16
ACEi or ARB therapy % 39
Outcomes
Remission %
Complete 29
Partial 39
No remission 32
Rate of change in renal functiona −0.37 ± 0.79
Relapse % 37
Renal failure % 12
aMeasured as change in slope of creatinine clearance (mL/min/month).
patients had a PR, 102 at least one CR, and 110 had NR.
Eighty percent of patients who satisfied the definition for
PR had another consecutive proteinuria measurement to
confirm this diagnosis. These patients had a rate of renal
function decline identical to the remaining 20% with only
one proteinuria. Forty-eight reached renal failure, 12 died
without renal failure, and 46 were still followed as of the
end of March, 2003. Two hundred and forty-two patients
had no clinical information recorded since March 2000
and were considered lost to follow-up. The median du-
ration of observation in the latter group was 58 months;
their average slope was −0.27 ± 0.72 mL/min/month, and
at last follow-up most (60%) were non-nephrotic.
Clinical and laboratory variables at onset and over
follow-up were tested for association with either renal
survival or the rate of renal function decline (slope). The
univariate determinants that predicted better renal sur-
vival were a higher initial CrCl, lower proteinuria at on-
set, PR, CR, lower time-average MAP, and the use of
ACEi or ARB (Fig. 1 and Table 2). Cox proportional
hazard regression identified CrCl and proteinuria at on-
set, PR, and CR as independent predictors (Table 2). The
adjusted hazard ratio for progression to renal failure af-
ter a PR was 0.08 in reference to NR (95%CI 0.03–0.19,
P < 0.001).
In terms of the rate of renal function decline, the uni-
variate determinants of a flatter slope (less progressive)
were female gender, lower proteinuria at onset, lower
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Fig. 1. Survival from renal failure in patients with complete, partial,
and no remission. Five patients out of 348 had a creatinine clearance
below 15 mL/min at the initial assessment and were excluded from this
analysis.
time-average blood pressure, PR, and CR. The slope in
those with a PR was significantly better than in the NR
group (slope −0.17 ± 0.50 in PR and −0.86 ± 1.08 in NR,
Student t test, P < 0.001). The creatinine clearance, race,
MAP, and age at onset and exposure to immunosuppres-
sion or ACE inhibition or ARB therapy did not correlate
with the slope. By multivariate analysis, only PR and CR
independently predicted slope (standardized b 0.45 and
0.46 for CR and PR, respectively, P < 0.001 for both, R2 =
0.20). The influence of PR on the rate of progression is
further supported by the improvement in slope seen after
remission (slope before vs. after −0.44 ± 0.79 and −0.16
± 0.65 mL/min/month, paired t test, N = 79, P = 0.03).
For both multivariate linear and Cox proportional regres-
sions, using different methods of entry of variables into
the models (forward, backward, or block entry) and con-
trolling for clinically relevant variables not predictive by
univariate analysis (e.g., age at onset) did not change the
estimates for PR. For survival analysis, the hazard ratio
with or without a given risk factor was relatively constant
over the observation period. Finally, the adjusted hazard
ratio for PR expressed as a time-dependent variable was
0.17 in reference to NR (95%CI 0.09–0.33, P < 0.001) and
similar to the one shown in Table 2.
Patients with PR were compared to CR and NR groups
to identify predictors of this outcome (Table 3). This
analysis used only information up until remission for
PR and CR. Compared to NR, partial remissions could
only be predicted by a preremission lower MAP. When
compared to CR, the PR group had a lower CrCl at on-
set and a higher follow-up MAP, despite receiving more
antihypertensive drugs. Immunosuppressive therapy was
not found predictive of remission in this retrolective
study (Table 3). When patients with no treatment were
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Table 2. Univariate and multivariate determinants of renal failure
Univariate Multivariate
Hazard ratio Hazard ratio
(95% CI) P value (95% CI) P value
At onset
CrCl mL/min 0.97 (0.96–0.99) <0.001 0.97 (0.96–0.99) <0.001
Proteinuria g/d 1.07 (1.02–1.13) 0.008 1.08 (1.02–1.15) 0.009
Follow-up
MAPa <0.001
Low 1 high<mid<low 1
Mid 3.62 (1.07–12.23) 0.92 (0.25–3.33) NS
High 9.09 (2.71–30.51) 1.73 (0.48–6.24) NS
Remission
NR 1 <0.001 1
PR 0.17 (0.09–0.33) NR<PR<CR 0.08 (0.03–0.19)b <0.001
CR –b –b –
ACEi or ARB therapy 0.41 (0.21–0.82) 0.009 0.90 (0.41–1.98) NS
Sex, race, age, BMI, and MAP at onset and immunosuppressive therapy were not predictive of renal survival by univariate analysis.
aMAP divided into 3 categories low (<130/80 mmHg), high (>140/90 mmHg) and mid (in between).
bBecause no patients in the CR group developed renal failure, no hazard ratio could be calculated.
Table 3. Comparison of complete, partial, and no remissiona
NR PR CR P value Post-hoc
N 110 136 102
At onset
Sex (% female) 23 30 41 0.01 NR<CR
Race (% cauc/AA/Asian/other) 79/7/4/10 80/3/5/12 75/6/3/16 NS
Age years 46 ± 16 50 ± 15 48 ± 14 NS
MAP mm Hg 104 ± 13 103 ± 13 102 ± 14 NS
CrCl mL/min 82 ± 37 79 ± 31 94 ± 31 0.004 NR,PR<CR
Proteinuria g/d 7.5 (0.9–31.3) 6.6 (0.8–26.2) 5.3 (0.5–27.0) 0.03 NR<CR
Follow-upb
Duration of follow-up months 34 (12–327) 67 (12–376) 87 (14–400) <0.001 NR<PR<CR
Time to remission months 23 (1–194) 30 (2–195) 0.003
MAP mm Hg 104 ± 9 100 ± 8 97 ± 8 <0.001 NR>PR>CR
Antihypertensive meds No. 0.8 (0–3.2) 0.6 (0–3.0) 0.3 (0–3.1) 0.003 NR,PR<CR
Immunosuppression %
None 47 34 43 NS
Mono 44 53 39
Dual 9 13 18
ACEi or ARB therapy % 31 32 23 NS
Outcome
Slope mL/min/month −0.86 ± 1.08 −0.17 ± 0.50 −0.12 ± 0.40 <0.001 NR>PR,CR
Relapse % – 47 23
Renal failure % 29 9 0 <0.001c NR>PR>CR
Abbreviations are: NS, not significant at 0.05 level; Cr, creatinine; cauc, Caucasian; AA, African American. a, Log-rank test.
aNormally distributed variables (expressed as mean ± standard deviation) are compared using one-way ANOVA with post-hoc analysis using the least significant
difference method for significant results. Nonparametric variables (expressed as median and range) are compared using Kruskal-Wallis with post-hoc analysis using the
Mann-Whitney test for significant results. Categorical variables are expressed in percentage and compared using chi-square test.
bInformation up until remission for PR and CR groups.
cLog-rank test.
compared to those receiving dual therapy within each
group, patients with PR and CR did not receive more
dual therapy than NR (16% vs. 28% and 29% for NR,
PR, and CR, respectively, N = 188, chi-square, P = NS).
By limiting this analysis to high-risk of progression pa-
tients with sustained proteinuria >6 g/day over 6 months
[19], a benefit to immunosuppression with dual therapy
was seen (30% vs. 55% and 65% exposed to dual ther-
apy in NR, PR, and CR, respectively, N = 72, chi-square,
P = 0.02, NR compared to CR + PR).
Subjects with a PR in the setting of dual immunosup-
pressive therapy had a similar slope and renal survival
as spontaneous PR (Table 4). This group also had better
blood pressure control and more ACEi or ARB therapy
than the spontaneous remitters. The dual therapy group
did have a significant improvement in their slope after
remission in contrast to patients with a spontaneous PR
(Table 4).
Sixty-two patients in the PR group had a relapse af-
ter a median time of 8 [1–147] months in remission.
Twenty-nine in this group (29/62) had a second remission
either spontaneously or following immunosuppressive
therapy, and 17 of these (17/29) had multiple remissions
and relapses. There were five patients with no follow-up
Troyanov et al: Partial remissions in membranous nephropathy 1203
Table 4. Comparison of partial remissions in those treated with dual
versus no immunosuppression
Dual treatment No treatment P value
N 18 46
At onset
Sex (% female) 39 28 NS
Age 54 ± 14 51 ± 15 NS
CrCl mL/min 70 ± 36 85 ± 28 NS
Proteinuria g/d 6.9 (2–22) 5.9 (1.1–15.5) NS
MAP mm Hg 101 ± 13 103 ± 12 NS
Duration of follow-up
Total months 52 (19–146) 54 (12–376) NS
Onset to remission months 24 (3–107) 16 (1–194) NS
At start immunosuppression
CrCl mL/min 61 ± 30 –
Proteinuria g/d 9.7 (4–40) –
MAP mm Hg 101 ± 13 –
At remission
CrCl mL/min 59 ± 27 78 ± 32 0.04
MAP mm Hg 94 ± 9 100 ± 8 0.02
ACEi or ARB therapy % 61 29 0.02
Outcome
Slopea before −0.63 ± 0.63 −0.27 ± 0.91
Slope after +0.28 ± 0.56 −0.39 ± 0.51
Paired t test, P 0.03 NS
Relapse % 28 50 NS
Renal failure % 6 4 NSb
aSlopes (mL/min/month) determined over the total follow-up were not
different between groups.
bLog-rank test.
information after PR. The median peak proteinuria dur-
ing the first relapse was 6.9 g/day (3.8–41.0). Duration of
follow-up after PR was 55 [1–248] months in relapsers
compared to 29 (1–275) in nonrelapsers (P = 0.001). No
variable helped identify patients likely to relapse (data
not shown). Patients who never relapsed did have a sig-
nificant improvement in their slope after remission, in
contrast to those who relapsed (slope before vs. after
−0.40 ± 0.65 and 0.02 ± 0.40, N = 39, P = 0.007, paired
t test, compared to −0.47 ± 0.91 and −0.34 ± 0.78, N =
40, P = NS, paired t test), although their renal survival
was not different. Patients in remission at last follow-up
(no relapse or any number of relapse followed by remis-
sion) were less likely to have progressed to renal failure
(hazard ratio 0.24, 95%CI 0.07–0.82, P = 0.01).
DISCUSSION
The long-term outcome in MGN nephropathy has been
reported many times over the past 20 years. Outcome has
classically been divided into three groups: complete re-
mission, progression to renal failure, or continuing pro-
teinuria [20, 21]. The latter category includes those that
never remitted, partial remitters, and those that have re-
lapsed from complete or partial remission. The definition
of a PR has varied, and none of them have definitively
been tied to an improved prognosis, despite its use as a
surrogate outcome. This analysis of MGN patients from
the Toronto glomerulonephritis registry was undertaken
to establish partial remission in proteinuria as a valid sur-
rogate end point predictive of both survival from renal
failure and the rate of progression of renal disease.
This review included 348 patients with a median follow-
up of five years. Although 242 patients were lost to follow-
up, this was only after a five-year observation time and
these patients were predominantly doing well, as indi-
cated by their slow rate of renal function decline and
the high proportion of non-nephrotic patients at last
follow-up. Prospective studies of this size and length are
unlikely to be conducted, and the slow evolution of this
disease does not allow conclusions to be drawn on definite
end points, such as renal failure over shorter observation
times. Hence, establishing additional standardized and
valid early predictors of outcome in MGN are important
and currently can only be made from large longitudinal
population studies.
We found that in addition to a CR, achieving a PR
independently slowed the rate of renal function decline
and the risk of renal failure. As shown in previous stud-
ies, by univariate analysis, gender, CrCl and proteinuria
at onset, blood pressure, ACEi or ARB therapy were as-
sociated with our main outcomes [8, 22–26], but the im-
pact of PR dominated these by multivariate analysis. The
definition of PR is an important one. We used the same
definition as in our previous trials [15, 27] in our analyses
(i.e., both obtaining subnephrotic proteinuria levels and
a 50% reduction in peak proteinuria). Different defini-
tions are seen in the literature but overall they are similar
to ours and are unlikely to alter the strength of the asso-
ciation with renal survival found in this analysis [12–14,
28]. The adjusted hazard ratio obtained for a PR defined
solely by a 50% reduction from the peak proteinuria was
less discriminant (0.17, 95% CI 0.08–0.37, P < 0.001), and
when we use only a 50% decrease in proteinuria without
reaching subnephrotic range the renal survival was not
statistically superior to NR (univariate hazard ratio 0.75;
95% CI 0.36–1.54, P = NS). The present study deliber-
ately did not include stable creatinine in the definition of
PR to avoid introducing a bias that would inevitably lead
to a greater renal survival in that group because stable
renal function and renal survival are clearly strongly as-
sociated. However, we did exclude the diagnosis of PR
once the CrCl permanently dropped below 15 mL/min
because proteinuria is often reduced at low glomerular
filtration rates.
Our study did not find any clinical or laboratory vari-
ables either at onset or over time other than a lower
follow-up blood pressure that could predict a PR. This
was in contrast to patients who experienced a CR who
were significantly different in regards to sex distribution
(more females) and had a higher CrCl and lower protein-
uria at presentation. It is possible that some NR did not
have a sufficient observation period to reach a remission
because they were followed for a shorter duration. Such
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misclassification could account in part for our inability to
predict those who will have a PR, although part of this
shorter follow-up is secondary to a rapid progression to
the end point of renal failure. Certainly, the marked dif-
ferences in slope and renal survival between NR and PR
would suggest they are two distinct populations.
Two other important issues, although not the main
thrust of our study, are worthy of comment: the influ-
ence of immunosuppression, and the impact of ACEi or
ARB therapy. The impact of specific immunosuppres-
sive therapy was difficult to determine considering the
multitude of regimens tested over the past three decades
[29–31] and hence, it did not seem reasonable to classify
patients solely by exposure to any immunosuppressive
medication. The most recent and best evidence demon-
strating the efficacy of immunosuppression comes from
studies using dual therapies [12–15]. Even in these tri-
als, different regimens and populations were studied. We
therefore categorized patients, as have other authors, into
those who received no, mono-, or dual immunosuppres-
sive therapy [11]. The population treated could also intro-
duce a bias. Most MGN patients at low risk of progression
(i.e., those with low-level proteinuria, no edema, renal in-
sufficiency, or hypertension) are not likely to be treated
except for symptoms. These subjects perhaps should not
be compared to those who receive the most intensive im-
munotherapy because they have a much better prognosis.
This may explain some of the variance between conclu-
sions drawn from meta-analysis studies and randomized
controlled trials [15, 19, 32–36]. These issues may also
explain why an association between remissions and dual
treatment was only seen in a subset of our patients likely
to have progressive nephropathy. Some additional sup-
port for a benefit to immunosuppression comes from a
subgroup analysis of these patients. Those treated with
dual immunosuppressive therapy had a significant im-
provement in their slope after remission in contrast to
patient with spontaneous PR. Although this data suggests
a direct therapeutic effect, given their disease course ap-
pears to have been significantly altered by the drugs, we
are cautious about drawing these conclusions because of
the issues related to selection bias, subgroup analyses,
and other problems with retrolective studies. We have
included the data primarily to emphasize the point that
a PR, regardless how achieved, impacts on disease pro-
gression in MGN.
The second issue is the specific role of ACEi or ARB
therapy in MGN. Exposure to these medications was as-
sociated by univariate analysis with improved renal sur-
vival, but not with the rate of renal function decline as
measured by slope. By multivariate analysis, even the ef-
fect on renal survival was lost. This does not mean there
is no benefit to ACEi or ARB therapy in MGN, and cer-
tainly, other studies have indicated a specific renal benefit
with these drugs in nondiabetic proteinuric renal disease
beyond blood pressure control [9]. Possible explanations
for not finding this in our study are multiple. Many pa-
tients in this review predated these classes of drugs or had
them available only at the end of their disease process.
In addition, the classification into any exposure to ACEi
or ARB medication does not account for the duration
and intensity of therapy. Perhaps most importantly, par-
tial and complete remissions are so strongly associated
with renal survival that variables weakly associated with
this outcome are eliminated after multivariate analysis
(Table 2).
Finally, there was a high rate of relapse and subse-
quent remissions following PR, illustrating the variable
nature of MGN. Those who did not relapse had a sta-
tistically significant improvement in their slope after re-
mission, strengthening the importance of maintaining
non-nephrotic proteinuria, although even an unsustained
PR is important because they still had a better prognosis
than the NR.
CONCLUSIOIN
This study has shown that partial remissions, as defined
by both a 50% reduction in peak proteinuria and achiev-
ing a sub-nephrotic level, is a valid and important thera-
peutic goal for the clinician to target because its achieve-
ment is strongly correlated with both a reduction in the
rate of renal disease progression, and ultimately, a better
renal survival.
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